{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:13:20Z","timestamp":1792062800909,"version":"4.4.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2009,12,8]],"date-time":"2009-12-08T00:00:00Z","timestamp":1260230400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2009,12,8]],"date-time":"2009-12-08T00:00:00Z","timestamp":1260230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1038\/tpj.2009.63","type":"journal-article","created":{"date-parts":[[2009,12,8]],"date-time":"2009-12-08T17:07:55Z","timestamp":1260292075000},"page":"418-430","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":83,"title":["Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions"],"prefix":"10.1038","volume":"10","author":[{"given":"C T","family":"Correia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J P","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P E","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A F","family":"Sequeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C E","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T S","family":"Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R L","family":"Abreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G G","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A M","family":"Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,12,8]]},"reference":[{"key":"BFtpj200963_CR1","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1017\/S0012162205000952","volume":"47","author":"K Francis","year":"2005","unstructured":"Francis K . Autism interventions: a critical update. Dev Med Child Neurol 2005; 47: 493\u2013499.","journal-title":"Dev Med Child Neurol"},{"key":"BFtpj200963_CR2","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1542\/peds.2007-0984","volume":"121","author":"DS Mandell","year":"2008","unstructured":"Mandell DS, Morales KH, Marcus SC, Stahmer AC, Doshi J, Polsky DE . Psychotropic medication use among Medicaid-enrolled children with autism spectrum disorders. Pediatrics 2008; 121: 441\u2013448.","journal-title":"Pediatrics"},{"key":"BFtpj200963_CR3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1177\/026988110201600113","volume":"16","author":"L Barnard","year":"2002","unstructured":"Barnard L, Young AH, Pearson J, Geddes J, O\u2019Brien G . A systematic review of the use of atypical antipsychotics in autism. J Psychopharmacol 2002; 16: 93\u2013101.","journal-title":"J Psychopharmacol"},{"key":"BFtpj200963_CR4","first-page":"545","volume":"32","author":"L West","year":"2006","unstructured":"West L, Waldrop J . Risperidone use in the treatment of behavioral symptoms in children with autism. Pediatr Nurs 2006; 32: 545\u2013549.","journal-title":"Pediatr Nurs"},{"key":"BFtpj200963_CR5","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1056\/NEJMoa013171","volume":"347","author":"JT McCracken","year":"2002","unstructured":"McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002; 347: 314\u2013321.","journal-title":"N Engl J Med"},{"key":"BFtpj200963_CR6","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1001\/archpsyc.55.7.633","volume":"55","author":"CJ McDougle","year":"1998","unstructured":"McDougle CJ, Holmes JP, Carlson DC, Pelton GH, Cohen DJ, Price LH . A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry 1998; 55: 633\u2013641.","journal-title":"Arch Gen Psychiatry"},{"key":"BFtpj200963_CR7","doi-asserted-by":"publisher","first-page":"e634","DOI":"10.1542\/peds.2003-0264-F","volume":"114","author":"S Shea","year":"2004","unstructured":"Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004; 114: e634\u2013e641.","journal-title":"Pediatrics"},{"key":"BFtpj200963_CR8","first-page":"CD005040","volume":"January 24","author":"OS Jesner","year":"2007","unstructured":"Jesner OS, Aref-Adib M, Coren E . Risperidone for autism spectrum disorder. Cochrane Database Syst Rev 2007; January 24: CD005040.","journal-title":"Cochrane Database Syst Rev"},{"key":"BFtpj200963_CR9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2217\/17410541.4.3.271","volume":"4","author":"C Correia","year":"2007","unstructured":"Correia C, Vicente A . Pharmacogenetics of risperidone response and induced side effects. Per Med 2007; 4: 271\u2013293.","journal-title":"Per Med"},{"key":"BFtpj200963_CR10","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0024-3205(02)01680-6","volume":"71","author":"DW Boulton","year":"2002","unstructured":"Boulton DW, DeVane CL, Liston HL, Markowitz JS . In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci 2002; 71: 163\u2013169.","journal-title":"Life Sci"},{"key":"BFtpj200963_CR11","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1007\/s002130051171","volume":"147","author":"MG Scordo","year":"1999","unstructured":"Scordo MG, Spina E, Facciola G, Avenoso A, Johansson I, Dahl ML . Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl) 1999; 147: 300\u2013305.","journal-title":"Psychopharmacology (Berl)"},{"key":"BFtpj200963_CR12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00210-003-0832-2","volume":"369","author":"UM Zanger","year":"2004","unstructured":"Zanger UM, Raimundo S, Eichelbaum M . Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004; 369: 23\u201337.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"BFtpj200963_CR13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0893-133X(97)00112-7","volume":"18","author":"J Arnt","year":"1998","unstructured":"Arnt J, Skarsfeldt T . Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998; 18: 63\u2013101.","journal-title":"Neuropsychopharmacology"},{"key":"BFtpj200963_CR14","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/374542a0","volume":"374","author":"LH Tecott","year":"1995","unstructured":"Tecott LH, Sun LM, Akana SF, Strack AM, Lowenstein DH, Dallman MF et al. Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature 1995; 374: 542\u2013546.","journal-title":"Nature"},{"key":"BFtpj200963_CR15","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1093\/hmg\/ddh137","volume":"13","author":"M Ribases","year":"2004","unstructured":"Ribases M, Gratacos M, Fernandez-Aranda F, Bellodi L, Boni C, Anderluh M et al. Association of BDNF with anorexia, bulimia and age of onset of weight loss in six European populations. Hum Mol Genet 2004; 13: 1205\u20131212.","journal-title":"Hum Mol Genet"},{"key":"BFtpj200963_CR16","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1093\/emboj\/19.6.1290","volume":"19","author":"SG Kernie","year":"2000","unstructured":"Kernie SG, Liebl DJ, Parada LF . BDNF regulates eating behavior and locomotor activity in mice. EMBO J 2000; 19: 1290\u20131300.","journal-title":"EMBO J"},{"key":"BFtpj200963_CR17","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/1097-4547(20000615)60:6<783::AID-JNR11>3.0.CO;2-M","volume":"60","author":"F Angelucci","year":"2000","unstructured":"Angelucci F, Mathe AA, Aloe L . Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered after haloperidol and risperidone administration. J Neurosci Res 2000; 60: 783\u2013794.","journal-title":"J Neurosci Res"},{"key":"BFtpj200963_CR18","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/01.jcp.0000203196.65710.2b","volume":"26","author":"HY Lane","year":"2006","unstructured":"Lane HY, Liu YC, Huang CL, Chang YC, Wu PL, Lu CT et al. Risperidone-related weight gain: genetic and nongenetic predictors. J Clin Psychopharmacol 2006; 26: 128\u2013134.","journal-title":"J Clin Psychopharmacol"},{"key":"BFtpj200963_CR19","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1038\/sj.npp.1301619","volume":"33","author":"XY Zhang","year":"2008","unstructured":"Zhang XY, Zhou DF, Wu GY, Cao LY, Tan YL, Haile CN et al. BDNF levels and genotype are associated with antipsychotic-induced weight gain in patients with chronic schizophrenia. Neuropsychopharmacology 2008; 33: 2200\u20132205.","journal-title":"Neuropsychopharmacology"},{"key":"BFtpj200963_CR20","volume-title":"Autism Treatment Evaluation Checklist (ATEC)","author":"B Rimland","year":"2000","unstructured":"Rimland B, Edelson SM (2000). Autism Treatment Evaluation Checklist (ATEC), Autism Research Institute, San Diego, USA."},{"key":"BFtpj200963_CR21","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1023\/A:1013299028321","volume":"31","author":"J Rojahn","year":"2001","unstructured":"Rojahn J, Matson JL, Lott D, Esbensen AJ, Smalls Y . The Behavior Problem Inventory: an instrument for the assessment of self-injury, stereotyped behavior, and agression\/destruction in individuals with developmental disabilities. J Autism Dev Disord 2001; 31: 577\u2013588.","journal-title":"J Autism Dev Disord"},{"key":"BFtpj200963_CR22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/0891-4222(95)00037-2","volume":"17","author":"MJ Tass\u00e9","year":"1996","unstructured":"Tass\u00e9 MJ, Aman MG, Hammer D, Rojahn J . The nisonger child behavior rating form: age and gender effects and norms. Res Dev Disabil 1996; 17: 59\u201375.","journal-title":"Res Dev Disabil"},{"key":"BFtpj200963_CR23","first-page":"303","volume":"23","author":"D Lonsdale","year":"2002","unstructured":"Lonsdale D, Shamberger RJ, Audhya T . Treatment of autism spectrum children with thiamine tetrahydrofurfuryl disulfide: a pilot study. Neuro Endocrinol Lett 2002; 23: 303\u2013308.","journal-title":"Neuro Endocrinol Lett"},{"key":"BFtpj200963_CR24","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1177\/1362361305053257","volume":"9","author":"K Ratliff-Schaub","year":"2005","unstructured":"Ratliff-Schaub K, Carey T, Reeves GD, Rogers MA . Randomized controlled trial of transdermal secretin on behavior of children with autism. Autism 2005; 9: 256\u2013265.","journal-title":"Autism"},{"key":"BFtpj200963_CR25","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/cbf.1561","volume":"27","author":"C Correia","year":"2009","unstructured":"Correia C, Santos P, Coutinho AM, Vicente AM . Characterization of pharmacogenetically relevant CYP2D6 and ABCB1 gene polymorphisms in a Portuguese population sample. Cell Biochem Funct 2009; 27: 251\u2013255.","journal-title":"Cell Biochem Funct"},{"key":"BFtpj200963_CR26","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/S0140-6736(05)62485-3","volume":"350","author":"A Hinney","year":"1997","unstructured":"Hinney A, Ziegler A, Nothen MM, Remschmidt H, Hebebrand J . 5-HT2A receptor gene polymorphisms, anorexia nervosa, and obesity. Lancet 1997; 350: 1324\u20131325.","journal-title":"Lancet"},{"key":"BFtpj200963_CR27","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.2307\/2531734","volume":"44","author":"SL Zeger","year":"1988","unstructured":"Zeger SL, Liang KY, Albert PS . Models for longitudinal data: a generalized estimating equation approach. Biometrics 1988; 44: 1049\u20131060.","journal-title":"Biometrics"},{"key":"BFtpj200963_CR28","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1055\/s-2007-973836","volume":"40","author":"J de Leon","year":"2007","unstructured":"de Leon J, Susce MT, Pan RM, Wedlund PJ, Orrego ML, Diaz FJ . A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. Pharmacopsychiatry 2007; 40: 93\u2013102.","journal-title":"Pharmacopsychiatry"},{"key":"BFtpj200963_CR29","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1089\/cap.2006.16.379","volume":"16","author":"GJ Pandina","year":"2006","unstructured":"Pandina GJ, Aman MG, Findling RL . Risperidone in the management of disruptive behavior disorders. J Child Adolesc Psychopharmacol 2006; 16: 379\u2013392.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"BFtpj200963_CR30","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/00004583-200202000-00007","volume":"41","author":"RP Malone","year":"2002","unstructured":"Malone RP, Maislin G, Choudhury MS, Gifford C, Delaney MA . Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness. J Am Acad Child Adolesc Psychiatry 2002; 41: 140\u2013147.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"BFtpj200963_CR31","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1176\/appi.ajp.161.6.1125","volume":"161","author":"A Martin","year":"2004","unstructured":"Martin A, Scahill L, Anderson GM, Aman M, Arnold LE, McCracken J et al. Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. Am J Psychiatry 2004; 161: 1125\u20131127.","journal-title":"Am J Psychiatry"},{"key":"BFtpj200963_CR32","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1542\/peds.110.3.e34","volume":"111","author":"A Turgay","year":"2002","unstructured":"Turgay A, Binder C, Snyder R, Fisman S . Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics 2002; 111: 34.","journal-title":"Pediatrics"},{"key":"BFtpj200963_CR33","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.biopsych.2006.02.032","volume":"61","author":"GM Anderson","year":"2007","unstructured":"Anderson GM, Scahill L, McCracken JT, McDougle CJ, Aman MG, Tierney E et al. Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biol Psychiatry 2007; 61: 545\u2013550.","journal-title":"Biol Psychiatry"},{"key":"BFtpj200963_CR34","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.4088\/JCP.v64n1113","volume":"64","author":"RL Findling","year":"2003","unstructured":"Findling RL, Kusumakar V, Daneman D, Moshang T, De Smedt G, Binder C . Prolactin levels during long-term risperidone treatment in children and adolescents. J Clin Psychiatry 2003; 64: 1362\u20131369.","journal-title":"J Clin Psychiatry"},{"key":"BFtpj200963_CR35","first-page":"109","volume":"37","author":"VL Ellingrod","year":"2003","unstructured":"Ellingrod VL, Lund BC, Miller D, Fleming F, Perry P, Holman TL et al. 5-HT2A receptor promoter polymorphism, -1438G\/A and negative symptom response to olanzapine in schizophrenia. Psychopharmacol Bull 2003; 37: 109\u2013112.","journal-title":"Psychopharmacol Bull"},{"key":"BFtpj200963_CR36","first-page":"161","volume":"13","author":"H Herken","year":"2003","unstructured":"Herken H, Erdal ME, Esgi K, Virit O, Aynacioglu AS . The relationship between the response to risperidone treatment and 5-HT2A receptor gene (T102C and 1438G\/A) polymorphism in schizophrenia. Bull Clin Psychopharmacol 2003; 13: 161\u2013166.","journal-title":"Bull Clin Psychopharmacol"},{"key":"BFtpj200963_CR37","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.biopsych.2005.12.018","volume":"61","author":"RL Myers","year":"2007","unstructured":"Myers RL, Airey DC, Manier DH, Shelton RC, Sanders-Bush E . Polymorphisms in the regulatory region of the human serotonin 5-HT2A receptor gene (HTR2A) influence gene expression. Biol Psychiatry 2007; 61: 167\u2013173.","journal-title":"Biol Psychiatry"},{"key":"BFtpj200963_CR38","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.biopsych.2004.06.020","volume":"56","author":"MJ Parsons","year":"2004","unstructured":"Parsons MJ, D\u2019Souza UM, Arranz MJ, Kerwin RW, Makoff AJ . The -1438A\/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity. Biol Psychiatry 2004; 56: 406\u2013410.","journal-title":"Biol Psychiatry"},{"key":"BFtpj200963_CR39","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0920-9964(98)00032-2","volume":"32","author":"MJ Arranz","year":"1998","unstructured":"Arranz MJ, Munro J, Sham P, Kirov G, Murray RM, Collier DA et al. Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizophr Res 1998; 32: 93\u201399.","journal-title":"Schizophr Res"},{"key":"BFtpj200963_CR40","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.pharmthera.2006.04.009","volume":"112","author":"I Cascorbi","year":"2006","unstructured":"Cascorbi I . Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther 2006; 112: 457\u2013473.","journal-title":"Pharmacol Ther"},{"key":"BFtpj200963_CR41","doi-asserted-by":"publisher","first-page":"987","DOI":"10.2217\/14622416.7.7.987","volume":"7","author":"Q Xing","year":"2006","unstructured":"Xing Q, Gao R, Li H, Feng G, Xu M, Duan S et al. Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. Pharmacogenomics 2006; 7: 987\u2013993.","journal-title":"Pharmacogenomics"},{"key":"BFtpj200963_CR42","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1002\/jps.20717","volume":"95","author":"NN Salama","year":"2006","unstructured":"Salama NN, Yang Z, Bui T, Ho RJ . MDR1 haplotypes significantly minimize intracellular uptake and transcellular P-gp substrate transport in recombinant LLC-PK1 cells. J Pharm Sci 2006; 95: 2293\u20132308.","journal-title":"J Pharm Sci"},{"key":"BFtpj200963_CR43","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/FPC.0b013e3282f70458","volume":"18","author":"AJ Aarnoudse","year":"2008","unstructured":"Aarnoudse AJ, Dieleman JP, Visser LE, Arp PP, van der Heiden IP, van Schaik RH et al. Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration. Pharmacogenet Genomics 2008; 18: 299\u2013305.","journal-title":"Pharmacogenet Genomics"},{"key":"BFtpj200963_CR44","first-page":"3246","volume":"9","author":"RH Mathijssen","year":"2003","unstructured":"Mathijssen RH, Marsh S, Karlsson MO, Xie R, Baker SD, Verweij J et al. Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res 2003; 9: 3246\u20133253.","journal-title":"Clin Cancer Res"},{"key":"BFtpj200963_CR45","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jpsychires.2006.10.002","volume":"42","author":"N Bozina","year":"2008","unstructured":"Bozina N, Kuzman MR, Medved V, Jovanovic N, Sertic J, Hotujac L . Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients. J Psychiatr Res 2008; 42: 89\u201397.","journal-title":"J Psychiatr Res"},{"key":"BFtpj200963_CR46","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1097\/01.ftd.0000246761.82377.a6","volume":"28","author":"YC Lin","year":"2006","unstructured":"Lin YC, Ellingrod VL, Bishop JR, Miller del D . The relationship between P-glycoprotein (PGP) polymorphisms and response to olanzapine treatment in schizophrenia. Ther Drug Monit 2006; 28: 668\u2013672.","journal-title":"Ther Drug Monit"},{"key":"BFtpj200963_CR47","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.jpsychires.2007.10.007","volume":"42","author":"M Alenius","year":"2008","unstructured":"Alenius M, Wadelius M, Dahl ML, Hartvig P, Lindstrom L, Hammarlund-Udenaes M . Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting. J Psychiatr Res 2008; 42: 884\u2013893.","journal-title":"J Psychiatr Res"},{"key":"BFtpj200963_CR48","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/01.jcp.0000150226.84371.76","volume":"25","author":"HY Lane","year":"2005","unstructured":"Lane HY, Hsu SK, Liu YC, Chang YC, Huang CH, Chang WH . Dopamine D3 receptor Ser9Gly polymorphism and risperidone response. J Clin Psychopharmacol 2005; 25: 6\u201311.","journal-title":"J Clin Psychopharmacol"},{"key":"BFtpj200963_CR49","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.euroneuro.2004.07.001","volume":"15","author":"GP Reynolds","year":"2005","unstructured":"Reynolds GP, Yao Z, Zhang X, Sun J, Zhang Z . Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response. Eur Neuropsychopharmacol 2005; 15: 143\u2013151.","journal-title":"Eur Neuropsychopharmacol"},{"key":"BFtpj200963_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ajmg.b.20045","volume":"124B","author":"G Szekeres","year":"2004","unstructured":"Szekeres G, Keri S, Juhasz A, Rimanoczy A, Szendi I, Czimmer C et al. Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2004; 124B: 1\u20135.","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"BFtpj200963_CR51","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1176\/appi.ajp.162.3.613","volume":"162","author":"PR Buckland","year":"2005","unstructured":"Buckland PR, Hoogendoorn B, Guy CA, Smith SK, Coleman SL, O\u2019Donovan MC . Low gene expression conferred by association of an allele of the 5-HT2C receptor gene with antipsychotic-induced weight gain. Am J Psychiatry 2005; 162: 613\u2013615.","journal-title":"Am J Psychiatry"},{"key":"BFtpj200963_CR52","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0024-3205(00)00911-5","volume":"68","author":"E Richelson","year":"2000","unstructured":"Richelson E, Souder T . Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 2000; 68: 29\u201339.","journal-title":"Life Sci"},{"key":"BFtpj200963_CR53","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1016\/S0140-6736(02)08913-4","volume":"359","author":"GP Reynolds","year":"2002","unstructured":"Reynolds GP, Zhang ZJ, Zhang XB . Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 2002; 359: 2086\u20132087.","journal-title":"Lancet"},{"key":"BFtpj200963_CR54","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.pnpbp.2006.12.021","volume":"31","author":"S Ryu","year":"2007","unstructured":"Ryu S, Cho EY, Park T, Oh S, Jang WS, Kim SK et al. 759 C\/T polymorphism of 5-HT2C receptor gene and early phase weight gain associated with antipsychotic drug treatment. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 673\u2013677.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"BFtpj200963_CR55","first-page":"1097","volume":"82","author":"Z Zhang","year":"2002","unstructured":"Zhang Z, Zhang X, Yao Z, Chen J, Sun J, Yao H et al. Association of antipsychotic agent-induced weight gain with a polymorphism of the promotor region of the 5-HT2C receptor gene]. Zhonghua Yi Xue Za Zhi 2002; 82: 1097\u20131101.","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"BFtpj200963_CR56","first-page":"929","volume":"3","author":"DL Torre","year":"2007","unstructured":"Torre DL, Falorni A . Pharmacological causes of hyperprolactinemia. Ther Clin Risk Manag 2007; 3: 929\u2013951.","journal-title":"Ther Clin Risk Manag"},{"key":"BFtpj200963_CR57","doi-asserted-by":"publisher","first-page":"3572","DOI":"10.1523\/JNEUROSCI.21-10-03572.2001","volume":"21","author":"LD Van de Kar","year":"2001","unstructured":"Van de Kar LD, Javed A, Zhang Y, Serres F, Raap DK, Gray TS . 5-HT2A receptors stimulate ACTH, corticosterone, oxytocin, renin, and prolactin release and activate hypothalamic CRF and oxytocin-expressing cells. J Neurosci 2001; 21: 3572\u20133579.","journal-title":"J Neurosci"},{"key":"BFtpj200963_CR58","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1159\/000127089","volume":"63","author":"IM Lacau-Mengido","year":"1996","unstructured":"Lacau-Mengido IM, Libertun C, Becu-Villalobos D . Different serotonin receptor types participate in 5-hydroxytryptophan-induced gonadotropins and prolactin release in the female infantile rat. Neuroendocrinology 1996; 63: 415\u2013421.","journal-title":"Neuroendocrinology"},{"key":"BFtpj200963_CR59","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1192\/bjp.185.2.147","volume":"185","author":"RM Young","year":"2004","unstructured":"Young RM, Lawford BR, Barnes M, Burton SC, Ritchie T, Ward WK et al. Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele. Br J Psychiatry 2004; 185: 147\u2013151.","journal-title":"Br J Psychiatry"},{"key":"BFtpj200963_CR60","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.pnpbp.2008.05.006","volume":"32","author":"N Yasui-Furukori","year":"2008","unstructured":"Yasui-Furukori N, Saito M, Tsuchimine S, Nakagami T, Sato Y, Sugawara N et al. Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1491\u20131495.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"BFtpj200963_CR61","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.tins.2004.08.001","volume":"27","author":"MP Mattson","year":"2004","unstructured":"Mattson MP, Maudsley S, Martin B . BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders. Trends Neurosci 2004; 27: 589\u2013594.","journal-title":"Trends Neurosci"},{"key":"BFtpj200963_CR62","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00213-002-1016-3","volume":"161","author":"FI Tarazi","year":"2002","unstructured":"Tarazi FI, Zhang K, Baldessarini RJ . Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions. Psychopharmacology (Berl) 2002; 161: 263\u2013270.","journal-title":"Psychopharmacology (Berl)"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/tpj200963.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj200963","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj200963.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T10:17:19Z","timestamp":1647944239000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/tpj200963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,8]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["BFtpj200963"],"URL":"https:\/\/doi.org\/10.1038\/tpj.2009.63","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12,8]]},"assertion":[{"value":"26 June 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2009","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2009","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2009","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}